CAPR Latest Headlines

Capricor’s HOPE-3 extension data point to a 76% slowdown in upper-limb decline after patients start Deramiocel

Market Chameleon (Mon, 5-Oct 11:47 AM)

Capricor Highlights HOPE-3 Extension Data Showing a 76% Slowdown in Upper-Limb Decline After Switching From Placebo

Market Chameleon (Mon, 5-Oct 9:46 AM)

CAPR trades higher as lead-plaintiff deadline arrives for Deramiocel-related securities class action

Market Chameleon (Wed, 30-Sep 10:28 AM)

CAPR Faces November 22 FDA Decision Date as Securities Class Action Lead Plaintiff Deadline Nears

Market Chameleon (Fri, 18-Sep 11:58 AM)

Capricor to spotlight HOPE-3 24-month outcomes at WMS 2026 as Deramiocel faces a Nov. 22, 2026 PDUFA date

Market Chameleon (Thu, 17-Sep 8:42 AM)

Class Action Lawsuit Casts Spotlight on Capricor Therapeutics: What Investors Need to Know Before September 28, 2026

Market Chameleon (Wed, 26-Aug 11:06 AM)

Capricor Faces Class Action Lawsuit Over Deramiocel FDA Dispute—Investors Eye September 28, 2026 Deadline

Market Chameleon (Tue, 25-Aug 10:32 AM)

CAPR Faces Class Action Lawsuit Amid Historic Stock Drop Tied to FDA Concerns Over Deramiocel

Market Chameleon (Mon, 24-Aug 11:08 AM)

FDA Extends Review of Capricor’s Deramiocel as New Phase 3 Data Strengthens Case for Duchenne Therapy

Market Chameleon (Mon, 24-Aug 9:33 AM)

Deramiocel’s FDA Path and Lancet-Published Results Drive Renewed Attention to Capricor—BLA Review, Clinical Milestones, and Financials in Focus

Market Chameleon (Fri, 14-Aug 9:52 AM)